CN1052398C - 球状药用制剂 - Google Patents
球状药用制剂 Download PDFInfo
- Publication number
- CN1052398C CN1052398C CN92105698A CN92105698A CN1052398C CN 1052398 C CN1052398 C CN 1052398C CN 92105698 A CN92105698 A CN 92105698A CN 92105698 A CN92105698 A CN 92105698A CN 1052398 C CN1052398 C CN 1052398C
- Authority
- CN
- China
- Prior art keywords
- controlled release
- globose nucleus
- weight
- coating material
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Fertilizers (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
一种受控释放组合物,包括由硫氮酮或其药学上可接受的盐和可选的成球剂组成的球状核,所述核被一种受控释放材料涂覆。如果加入成球剂的话,最好选用微晶纤维素。乙基纤维素是优选的受控释放涂层。受控释放涂层最好包含增塑剂、表面活性剂和胶粘改性剂。
Description
本发明涉及一种受控释放制剂及其制备方法,尤其涉及含硫氮酮的控制释放制剂。
硫氮酮是一种钙拮抗剂,可用来治疗心脏病,例如心胶病和高血压。
本发明的目的是提供一种受控释放硫氮酮制剂,适于每日一次给药,治疗高血压和心绞痛。
因此,本发明提供包含球状核的受控释放制剂,该核由硫氮酮或其药学上可接受的盐组成,还可含有成球剂,并覆有受控释放层。
本发明所用的适当的药学上可接受的盐包括药学上可接受的酸加成盐。特别优选盐酸盐。
本发明的受控释放药用组合物能够在较长时间内缓慢释放药物,并且在该时间内延长药物作用时间以达到常规药物传送的效果。
“球状”一词是药学领域的常用词,它是指直径为0.1mm~2.5mm;尤其是0.5mm~2mm的球状粒子。
本发明球状核最好含40%~98%,含60%~85%更好,尤其含70%~85%(重量)硫氮酮或其药学上可接受的盐。
成球剂可以是任何适当的药学上可接受的材料。它可以与活性成分一起成球以形成球状核。优选的成球剂是微晶纤维素,所用的微晶纤维素可以是,例如阿维塞尔PH107或阿维塞尔PH102(商品名,FMC公司)。一般来说,当存在成球剂时,它占球状核的1%~60%(重量),最好药15%~40%(重量)。
球状核还可含有其它药学上可接受赋形剂和稀释剂。使之易于成球,例如用糖(如蔗糖、右旋糖、麦芽糖或乳糖)或糖醇(例如甘露醇、木糖醇或山梨糖醇)。在球状核中还可含有着色剂。
球状核最好是涂覆允许硫氮酮在水性介质中控制速率释放的膜,适宜的涂膜材料可包括水不溶蜡和聚合物,例如聚甲基丙烯酸酯(例如商标为Eudragit的聚合物)或优选水不溶纤维素,特别是乙基纤维素。这膜涂层还可含水溶性聚合物,例如聚乙烯吡咯烷酮或最好是水溶性纤维素,例如羟丙基甲基纤维素和羟丙基纤维素。应当理解,水不溶材料与水溶性材料的比率取决于所要求的释放速度和所选村料的溶解度,水溶性聚合物与水不溶聚合物的比率以1∶20至1∶2为佳。受控释放涂层优选包括一种或多种本领域的常规增塑剂,例如酞酸二乙酯,但最好是癸二酸二丁酯;表面活性剂,例如山梨聚糖三油酸酯、山梨聚糖单月桂酸酯或优选多乙氧基醚80(商标为Tween80)和胶粘改性剂,例如滑石粉或优选胶质无水硅石。
当存在增塑剂时,其含量将取决于所选的特定增塑剂,一般,增塑剂的量为受控释放膜涂层的1%至25%(重量)。当存在表面活性剂时,其适宜存在量为受控膜涂层的1%至25%(重量)当存在胶粘改性剂时,其存在量也以受控释放膜涂层的1%至25%(重量)为宜。
优选的受控释放膜涂层包括50%至95%乙基纤维素,5%至15%胶质无水硅石,5%至15%癸二酸二丁酯和5%至15%多乙氧基醚80(商标为Tween80)。
采用传统涂覆方法例如流化床或槽式涂覆,可在含硫氮酮的球状核的表面形成受控释放涂膜层。该涂层材料可应用溶液或悬浮液,适宜的溶剂系统包括水、二氯甲烷、乙醇、甲醇、异丙醇和丙酮及其混合物。涂覆溶液或悬浮液优选含2%至60%(重量)、最好含2%至20%(重量)涂覆材料。
受控释放涂覆材料的用量取决于所要求的释放速率,但是一般为受控释放涂覆球体的1%至25%(重量),最好为2%至8%(重量)。
本发明含硫氮酮球体的制备方法包括以下步骤:
(a)将包括硫氮酮或其药学上可接受的盐、水和可选的成球剂的混合物成粒;
(b)挤压成粒混合物,得到挤出物;
(c)将挤出物成球,直至形成球状核;
(d)干燥球状核;并且
(e)膜涂覆球状核。
采用传统制药技术可将本发明组合物填充制成胶囊或压制成片剂。
本发明组合物的可适当地每日一次给药。一般每日一次给药,剂型中硫氮)酮或其药学上可接受的盐(优选硫氮酮盐酸盐)的含量为120mg~300mg。
为了更好地理解本发明,给出下述实施例,仅为说明而已。实施例1
制备了具有下述配方的胶囊
硫氮酮球状核
材料 毫克
硫氮酮盐酸盐U.S.P 120
微晶纤维素E.P(Avicel PH 101) 30.0
蒸馏水E.P 适量
150
受控释放膜涂层
材料 毫克
硫氮酮盐酸盐球状核 150
乙基纤维素N10 U.S.N.F 7.38胶质无水硅石E.P.(Aerosil 130) 0.988癸二酸二丁酯U.S.N.F. 0.742多乙氧基醚80 E.P.(Tween 80) 0.791二氯甲烷BS 1994 适量甲醇B.P.1973 适量
160胶囊制剂 mg硫氮酮受控释放球状体 160硬酯酸镁 EP 0.480明胶囊壳3号(Size 3)
采用高剪切混合器混合硫氮酮和微晶纤维素,该混合是湿式成粒,挤压后得到挤出物,成粒并置于流化床干燥器中干燥,所得球体过筛,得到粒径为0.85-1.7毫米。
将受控释放涂膜成分分散在二氯甲烷/甲醇溶剂体系中,应用到流化床涂敷器内的硫氮酮球状核上,得到的涂膜球体过筛,然后,在流化床涂覆器中,将含硫氮酮受控释放球体用双氢氯噻嗪和羟丙基甲基纤维素的分散体涂膜。
通过EP篮式装置(100转/分),用PH4.5EP磷酸盐缓冲液测定所得产品的溶解度。所得结果如下:
硫氮酮溶解度
时间(小时) 硫氮酮受控释放
球状体
2 23
3 37
4 48
5 57
6 63
8 72
10 77
12 81
15 86
20 90
Claims (14)
1.一种受控释放组合物的制备方法,所制备的组合物含有由硫氮酮或其药学上可接受的盐、水和微晶纤维素以及任意选择的一种糖和/或一种糖醇和/或一种着色剂;该方法包括:
(a)使由60%至98%重量的硫氮酮或其药学上可接受的盐、水和微晶纤维素以及任意选择的一种糖和/或一种着色剂组成的混合物形成颗粒;
(b)将该颗粒化的混合物挤压出,以得到一种挤出物;
(c)将该挤出物球状化直至球状核形成;
(d)使该球状核干燥;以及
(e)用受控释放的物质涂覆该球状核。
2.根据权利要求1的方法,其中该颗粒状混合物含有70%至85%重量的硫氮酮或其药学上可接受的盐。
3.根据权利要求1的方法,其中该微晶纤维素的含量为球状核重量的15%至40%。
4.根据权利要求1的方法,其中该受控释放涂覆材料包括一种水不溶的聚合物。
5.根据权利要求4的方法,其中涂覆材料包括乙基纤维素。
6.根据权利要求1至5的任一项权利要求的方法,其中受控释放物质进一步包括一种或多种增塑剂、表面活性剂和粘胶改性剂。
7.按照权利要求6的方法,其中受控释放涂层包括50%~95%乙基纤维素、5%~15%胶状无水硅石、5%~15%癸二酸二丁酯和5%~15%多乙氧基醚80。
8.按照权利要求1至5任一项权利要求的方法,其中,受控释放涂覆材料的用量为受控释放的组合物重量的2%~8%。
9.按照权利要求6的方法,其中受控释放涂覆材料的用量为受控释放的组合物重量的2%~8%。
10.按照权利要求7的方法,其中受控释放涂覆材料的用量为受控释放的组合物重量的2%~8%。
11.根据权利要求1至5的任一项权利要求的方法,其中包括进一步将在步骤(e)中已涂覆的球状核填充入胶囊中的步骤。
12.根据权利要求6的方法,其中包括进一步将在步骤(e)中已涂覆的球状核填充入胶囊中的步骤。
13.根据权利要求7的方法,其中包括进一步在步骤(e)中已涂覆的球状核填充入胶囊中的步骤、
14.根据权利要求8的方法,其中包括进一步将在步骤(e)中已涂覆的球状核填充入胶囊中的步骤。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9117361.7 | 1991-08-12 | ||
GB919117361A GB9117361D0 (en) | 1991-08-12 | 1991-08-12 | Oral dosage form |
GB919122967A GB9122967D0 (en) | 1991-10-29 | 1991-10-29 | Pharmaceutical composition |
GB9122967.4 | 1991-10-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1069408A CN1069408A (zh) | 1993-03-03 |
CN1052398C true CN1052398C (zh) | 2000-05-17 |
Family
ID=26299395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN92105698A Expired - Lifetime CN1052398C (zh) | 1991-08-12 | 1992-08-12 | 球状药用制剂 |
Country Status (14)
Country | Link |
---|---|
US (2) | US5670172A (zh) |
EP (1) | EP0527637B1 (zh) |
JP (1) | JP3019235B2 (zh) |
KR (1) | KR100221695B1 (zh) |
CN (1) | CN1052398C (zh) |
AT (1) | ATE165513T1 (zh) |
AU (1) | AU651715B2 (zh) |
CA (1) | CA2075356A1 (zh) |
DE (1) | DE69225278D1 (zh) |
ES (1) | ES2115643T3 (zh) |
FI (1) | FI923582A (zh) |
IL (1) | IL102778A (zh) |
NO (1) | NO304406B1 (zh) |
PH (1) | PH31288A (zh) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
FR2702160B1 (fr) * | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
SE9301220D0 (sv) * | 1993-04-14 | 1993-04-14 | Kabi Pharmacia Ab | Manufacturing matrices |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
US5834024A (en) * | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5914134A (en) * | 1997-01-27 | 1999-06-22 | Wockhardt Europe Limited | Process for the pulsatile delivery of diltiazem HCL and product produced thereby |
US7060734B1 (en) | 1997-09-09 | 2006-06-13 | Alza Corporation | Pharmaceutical coating composition and method of use |
AU9221898A (en) * | 1997-09-09 | 1999-03-29 | Alza Corporation | Pharmaceutical coating composition and method of use |
US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
HUP0100310A3 (en) * | 1997-12-22 | 2002-11-28 | Euro Celtique Sa | A method of preventing abuse of opioid dosage forms |
CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
BR0011522A (pt) | 1999-05-14 | 2002-06-04 | Nereus Pharmaceuticals Inc | Composto e método de sintetização para a fabricação do composto |
GB9913979D0 (en) | 1999-06-17 | 1999-08-18 | Univ Wales Medicine | Spheroid preparation |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
MXPA02004293A (es) | 1999-10-29 | 2002-10-31 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada.. |
US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
EP1299104B1 (en) | 2000-02-08 | 2009-05-13 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
JP2003523769A (ja) * | 2000-02-23 | 2003-08-12 | ヴァーテックス ファーマシューティカルズ (サンディエゴ)エルエルシー | 改変された蛍光タンパク質 |
US6852031B1 (en) * | 2000-11-22 | 2005-02-08 | Igt | EZ pay smart card and tickets system |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
EP1337244A4 (en) * | 2000-10-30 | 2006-01-11 | Euro Celtique Sa | HYDROCODON FORMULATIONS WITH CONTROLLED RELEASE |
ES2402045T3 (es) * | 2000-11-16 | 2013-04-26 | The Regents Of The University Of California | Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación |
TR200300731T2 (tr) | 2000-11-28 | 2004-08-23 | Fmc Corporation | Yenebilir PGA kaplama bileşimi |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
CA2454328C (en) | 2001-07-18 | 2008-03-18 | Christopher D. Breder | Pharmaceutical combinations of oxycodone and naloxone |
CA2457361C (en) | 2001-08-06 | 2008-11-04 | Christopher Breder | Opioid agonist formulations with releasable and sequestered antagonist |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
EP2425821B1 (en) | 2002-04-05 | 2017-05-10 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
EP2422773A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
US7112581B2 (en) * | 2002-09-27 | 2006-09-26 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US20040208932A1 (en) * | 2003-04-17 | 2004-10-21 | Ramachandran Thembalath | Stabilized paroxetine hydrochloride formulation |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
WO2005002572A2 (en) * | 2003-06-20 | 2005-01-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
EP2441767B1 (en) * | 2003-06-20 | 2015-06-10 | The Regents of The University of California | Salinosporamides and methods for use thereof |
US7727752B2 (en) * | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
CA2445420A1 (en) * | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
US7619059B2 (en) * | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
ATE458200T1 (de) * | 2003-09-12 | 2010-03-15 | Life Technologies Corp | Anwendungen des resonanzenergietransfers zwischen terbium und gfp |
KR20060132698A (ko) * | 2004-01-23 | 2006-12-21 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 항균제로 유용한 비스-인돌 피롤 |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
JP2007535559A (ja) | 2004-04-30 | 2007-12-06 | ネレアス ファーマシューティカルズ インコーポレイテッド | [3.2.0]複素環式化合物及びその使用法 |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
DE05852057T1 (de) | 2004-11-23 | 2007-11-29 | Neuromolecular Pharmaceuticals Inc., Emeryville | Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt |
WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
CN101155582B (zh) | 2004-12-03 | 2013-04-24 | 达纳-法伯癌症研究公司 | 治疗肿瘤性疾病的组合物和方法 |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
AU2006228536A1 (en) * | 2005-03-31 | 2006-10-05 | Rafael Armament Development Authority Ltd. | Spherically shaped substances |
DE602006016934D1 (de) | 2005-04-06 | 2010-10-28 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
ATE556046T1 (de) | 2005-07-21 | 2012-05-15 | Nereus Pharmaceuticals Inc | Interleukin-1- und tumornekrosefaktor-a- modulatoren, synthese solcher modulatoren und verfahren unter anwendung solcher modulatoren |
KR20140079441A (ko) | 2006-06-19 | 2014-06-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
AU2007275034A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
US20090017167A1 (en) * | 2007-07-11 | 2009-01-15 | Herbalife International Inc. | Mixture and beverage made therefrom for protecting cellular hydration |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
US20100266645A1 (en) * | 2007-12-17 | 2010-10-21 | Alfred Liang | Pharmaceutical compositions |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
RU2010129907A (ru) * | 2007-12-17 | 2012-01-27 | Лабофарм Инк. (CA) | Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
CN102089312A (zh) | 2008-05-12 | 2011-06-08 | 尼瑞斯药品公司 | 作为蛋白酶体抑制剂的Salinosporamide衍生物 |
WO2010003963A1 (en) * | 2008-07-07 | 2010-01-14 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
JP5886632B2 (ja) | 2009-03-10 | 2016-03-16 | ユーロ−セルティーク エス.エイ. | オキシコドンおよびナロキソンを含む即時放出医薬組成物 |
AU2010325960C1 (en) | 2009-12-02 | 2015-08-06 | Adamas Pharma, Llc | Amantadine compositions and methods of use |
US10463611B2 (en) | 2011-06-08 | 2019-11-05 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
ITFI20110172A1 (it) * | 2011-08-08 | 2013-02-09 | Valpharma Sa | Formulazione multiparticolata a rilascio modificato di diltiazem hcl. |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
KR20160034352A (ko) | 2013-07-23 | 2016-03-29 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
MX2017002750A (es) | 2014-09-02 | 2017-08-02 | Singh Bhupinder | Metodo para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento. |
WO2016057563A1 (en) | 2014-10-08 | 2016-04-14 | Pacific Northwest Diabetes Research Institute | Methods and compositions for increasing the potency of antifungal agents |
US10973783B2 (en) | 2015-12-30 | 2021-04-13 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
JP2021519367A (ja) | 2018-03-28 | 2021-08-10 | ハーバライフ・インターナショナル・オブ・アメリカ・インコーポレイテッド | 多糖のアセチル化 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0304105A1 (en) * | 1987-07-30 | 1989-02-22 | SCHELDE-DELTA, b.v.b.a. | Process and apparatus for fixing materials in a fluid stream |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
EP0322277A1 (fr) * | 1987-12-21 | 1989-06-28 | Synthelabo | Formulation pharmaceutique à libération prolongée |
EP0340105A1 (fr) * | 1988-04-27 | 1989-11-02 | Sanofi | Microbilles de diltiazem, leur procédé de fabrication et compositions pharmaceutiques à libération prolongée les contenant |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456628A (en) * | 1981-01-07 | 1984-06-26 | Bauer Kurt H | Process for film-coating a particulate solid, and emulsions for conducting the process |
DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
US4643731A (en) * | 1985-08-16 | 1987-02-17 | Alza Corporation | Means for providing instant agent from agent dispensing system |
JPS62103012A (ja) * | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | 多重顆粒 |
IT1200217B (it) * | 1986-09-30 | 1989-01-05 | Valducci Roberto | Membrana per uso farmaceutico ed industriale |
DE3709188A1 (de) * | 1987-03-20 | 1988-09-29 | Mannesmann Ag | Ausgiessrohr fuer metallurgische gefaesse |
GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
CA1323833C (en) * | 1987-04-28 | 1993-11-02 | Yatindra M. Joshi | Pharmaceutical compositions in the form of beadlets and method |
US4814181A (en) * | 1987-09-03 | 1989-03-21 | Alza Corporation | Dosage form comprising fast agent delivery followed by slow agent delivery |
US5219621A (en) * | 1987-10-16 | 1993-06-15 | Elan Corporation, Plc | Methods of treatment with diltiazem formulations |
DE3856555T2 (de) * | 1987-10-16 | 2004-04-29 | Elan Corp. Plc | Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption |
IL88083A (en) * | 1987-11-06 | 1992-11-15 | Tanabe Seiyaku Co | Controlled release pharmaceutical dosage form and its preparation |
DE3739779A1 (de) * | 1987-11-24 | 1989-06-08 | Beiersdorf Ag | Pharmazeutische praeparate |
FR2623714B1 (fr) * | 1987-11-26 | 1990-04-20 | Ethypharm Sa | Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu |
JP2643222B2 (ja) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
GB8805695D0 (en) * | 1988-03-10 | 1988-04-07 | Nycomed As | Enteric coated spheroidal granules |
FI101344B (fi) * | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta |
EP0373417A1 (en) * | 1988-11-30 | 1990-06-20 | Schering Corporation | Sustained release diltiazem formulation |
SE506179C2 (sv) * | 1989-01-23 | 1997-11-17 | Ciba Geigy Ag | Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum |
SE8902699D0 (sv) * | 1989-08-09 | 1989-08-09 | Lejus Medical Ab | Diltiazem containing pharmaceutical compositios |
JPH0674206B2 (ja) * | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
ZA923474B (en) * | 1991-05-20 | 1993-01-27 | Marion Merrell Dow Inc | Diltiazem formulation |
-
1992
- 1992-08-04 KR KR1019920013984A patent/KR100221695B1/ko not_active IP Right Cessation
- 1992-08-05 CA CA002075356A patent/CA2075356A1/en not_active Abandoned
- 1992-08-06 AU AU20880/92A patent/AU651715B2/en not_active Expired
- 1992-08-10 PH PH44791A patent/PH31288A/en unknown
- 1992-08-10 JP JP4234295A patent/JP3019235B2/ja not_active Expired - Lifetime
- 1992-08-10 IL IL10277892A patent/IL102778A/en not_active IP Right Cessation
- 1992-08-11 FI FI923582A patent/FI923582A/fi unknown
- 1992-08-11 ES ES92307333T patent/ES2115643T3/es not_active Expired - Lifetime
- 1992-08-11 DE DE69225278T patent/DE69225278D1/de not_active Expired - Lifetime
- 1992-08-11 AT AT92307333T patent/ATE165513T1/de active
- 1992-08-11 NO NO923128A patent/NO304406B1/no not_active IP Right Cessation
- 1992-08-11 EP EP92307333A patent/EP0527637B1/en not_active Expired - Lifetime
- 1992-08-12 CN CN92105698A patent/CN1052398C/zh not_active Expired - Lifetime
-
1995
- 1995-04-21 US US08/426,065 patent/US5670172A/en not_active Expired - Lifetime
-
1996
- 1996-06-18 US US08/666,636 patent/US5601845A/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
US4808413B1 (zh) * | 1987-04-28 | 1991-09-10 | Squibb & Sons Inc | |
EP0304105A1 (en) * | 1987-07-30 | 1989-02-22 | SCHELDE-DELTA, b.v.b.a. | Process and apparatus for fixing materials in a fluid stream |
EP0322277A1 (fr) * | 1987-12-21 | 1989-06-28 | Synthelabo | Formulation pharmaceutique à libération prolongée |
EP0340105A1 (fr) * | 1988-04-27 | 1989-11-02 | Sanofi | Microbilles de diltiazem, leur procédé de fabrication et compositions pharmaceutiques à libération prolongée les contenant |
Also Published As
Publication number | Publication date |
---|---|
FI923582A0 (fi) | 1992-08-11 |
JPH05201867A (ja) | 1993-08-10 |
ATE165513T1 (de) | 1998-05-15 |
ES2115643T3 (es) | 1998-07-01 |
IL102778A0 (en) | 1993-01-31 |
EP0527637A1 (en) | 1993-02-17 |
AU651715B2 (en) | 1994-07-28 |
DE69225278D1 (de) | 1998-06-04 |
PH31288A (en) | 1998-07-06 |
KR930003906A (ko) | 1993-03-22 |
KR100221695B1 (ko) | 1999-09-15 |
FI923582A (fi) | 1993-02-13 |
NO923128L (no) | 1993-02-15 |
US5601845A (en) | 1997-02-11 |
NO923128D0 (no) | 1992-08-11 |
EP0527637B1 (en) | 1998-04-29 |
IL102778A (en) | 1999-05-09 |
JP3019235B2 (ja) | 2000-03-13 |
NO304406B1 (no) | 1998-12-14 |
US5670172A (en) | 1997-09-23 |
AU2088092A (en) | 1993-02-18 |
CA2075356A1 (en) | 1993-02-13 |
CN1069408A (zh) | 1993-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1052398C (zh) | 球状药用制剂 | |
US9399025B2 (en) | Modified release dosage forms of skeletal muscle relaxants | |
CA2169376C (en) | Procedure for encapsulating nsaids | |
JP3061474B2 (ja) | 疏水性ポリマーの水分散液でコーティングされた安定な放出制御処方を得る方法 | |
Hari et al. | Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin | |
CA1252723A (en) | Controlled-release medical preparations | |
JP3350559B2 (ja) | 活性成分を含有する予め成形された微小粒子より製造される機械的に安定でかつ容易に分解し得る錠剤 | |
CA2433186C (en) | Delayed release pharmaceutical formulations | |
NO300797B1 (no) | Farmasöytisk kombinasjonsformulering inneholdende diltiazem og hydroklortiazid | |
SK148999A3 (en) | Gastroretentive controlled release microspheres for improved drug delivery | |
CZ284924B6 (cs) | Prostředek s řízeným uvolňováním, který obsahuje morfinovou sůl | |
KR20010031797A (ko) | 장기 지속 방출성 제형 | |
WO2005084636A2 (en) | A process for the preparation of controlled-release pharmaceutical composition of metoprolol | |
US20070092568A1 (en) | Galantamine compositions | |
JPS58116414A (ja) | ニカルジピン持続性製剤用球形顆粒およびその製造法 | |
MXPA06008854A (es) | Mini tabletas de clorhidrato de venlafaxina de liberacion prolongada recubiertas. | |
US5344657A (en) | Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them | |
FI100303B (fi) | Menetelmä suun kautta annettavan buspironin ja sen suolan valmistamise ksi | |
JPH03118335A (ja) | 風味マスキングされたマイクロカプセル化非ステロイド系抗炎症水不溶性薬剤 | |
US20070275066A1 (en) | Sustained release drug delivery system composed of water insoluble polymer | |
EP3892263A1 (en) | Oral dosage form | |
CA1336326C (en) | Microbeads of diltiazem, a process for their manufacture and a sustained-release pharmaceutical composition containing them | |
EP0608306B1 (en) | Peroral drug delivery system | |
JPH024575B2 (zh) | ||
JP3343144B2 (ja) | マイクロカプセル |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20120812 Granted publication date: 20000517 |